ArticleAtherosclerosis2017
Lack of myeloid Fatp1 increases atherosclerotic lesion size in Ldlr
Article in Atherosclerosis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Reprogramming macrophage metabolism for cardiovascular therapy: From molecular pathways to precision nanomedicine.Materials today. Bio · 2026Review
- Myeloid-specific fatty acid transport protein 4 deficiency induces a sex-dimorphic susceptibility for nonalcoholic steatohepatitis in mice fed a high-fat, high-cholesterol diet.American journal of physiology. Gastrointestinal and liver physiology · 2023Article
- Metabolite transporters as regulators of macrophage polarization.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Network analysis of transcriptomic diversity amongst resident tissue macrophages and dendritic cells in the mouse mononuclear phagocyte system.PLoS biology · 2020Article
- Metabolic Reprogramming of Macrophages in Atherosclerosis: Is It All about Cholesterol?Journal of lipid and atherosclerosis · 2020Review
- Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.Immunological reviews · 2020Review
- Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer.Frontiers in cell and developmental biology · 2020Review
- MyeloidJournal of immunology (Baltimore, Md. : 1950) · 2019Article
- The SLC transporter in nutrient and metabolic sensing, regulation, and drug development.Journal of molecular cell biology · 2019Article
- The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsAltered metabolism is an important regulator of macrophage (MΦ) phenotype, which contributes to inflammatory diseases such as atherosclerosis. Broadly, pro-inflammatory, classically-activated MΦs (CAM) are glycolytic while alternatively-activated MΦs (AAM) oxidize fatty acids, although overlap exists. We previously demonstrated that MΦ fatty acid transport protein 1 (FATP1, Slc27a1) was necessary to maintain the oxidative and anti-inflammatory AAM phenotype in vivo in a model of diet-induced obesity. The aim of this study was to examine how MΦ metabolic reprogramming through FATP1 ablation affects the process of atherogenesis. We hypothesized that FATP1 limits MΦ-mediated inflammation during atherogenesis. Thus, mice lacking MΦ Fatp1 would display elevated formation of atherosclerotic lesions in a mouse model lacking the low-density lipoprotein (LDL) receptor (Ldlr
methodsWe transplanted bone marrow collected from Fatp1
resultsCompared to Fatp1
conclusionsMΦ Fatp1 limits atherogenesis and may be a viable target to metabolically reprogram MΦs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.